These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38609880)

  • 41. Correlation of serum Mac-2-binding protein glycosylation isomer (M2BPGi) and liver stiffness in chronic hepatitis B infection.
    Mak LY; Wong DK; Seto WK; Ning Q; Cheung KS; Fung J; Lai CL; Yuen MF
    Hepatol Int; 2019 Mar; 13(2):148-156. PubMed ID: 30671807
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Magnitude of and prediction for risk of hepatocellular carcinoma in patients with chronic hepatitis B taking entecavir or tenofovir therapy: A systematic review.
    Tseng CH; Tseng CM; Wu JL; Hsu YC; El-Serag HB
    J Gastroenterol Hepatol; 2020 Oct; 35(10):1684-1693. PubMed ID: 32343431
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide-naïve chronic hepatitis B patients in Korea: data from the clinical practice setting in a single-center cohort.
    Ahn SS; Chon YE; Kim BK; Kim SU; Kim DY; Ahn SH; Han KH; Park JY
    Clin Mol Hepatol; 2014 Sep; 20(3):261-6. PubMed ID: 25320729
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Similar efficacy and safety of tenofovir in Asians and non-Asians with chronic hepatitis B.
    Pan CQ; Chan S; Trinh H; Yao A; Bae H; Lou L
    World J Gastroenterol; 2015 May; 21(18):5524-31. PubMed ID: 25987775
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hepatitis B core antibody and liver stiffness measurements predict HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients with minimally elevated alanine aminotransferase (ALT) levels.
    Fu X; Lou H; Chen F; Gao X; Lin Z
    Clin Exp Med; 2020 May; 20(2):241-248. PubMed ID: 32052245
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Liver fibrosis progression in chronic hepatitis B patients positive for hepatitis B e antigen: a prospective cohort study with paired transient elastography examination.
    Wong GL; Chan HL; Yu Z; Chan HY; Tse CH; Wong VW
    J Gastroenterol Hepatol; 2013 Nov; 28(11):1762-9. PubMed ID: 23808759
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A randomized open label trial of tenofovir monotherapy versus tenofovir plus telbivudine in spontaneous reactivation of hepatitis B.
    Jindal A; Vyas A; Sharma M; Kumar G; Sarin SK
    Saudi J Gastroenterol; 2019; 25(5):319-326. PubMed ID: 31044748
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Real-world single-center experience with entecavir and tenofovir disoproxil fumarate in treatment-naïve and experienced patients with chronic hepatitis B.
    Kim YM; Shin HP; Lee JI; Joo KR; Cha JM; Jeon JW; Yoon JY; Kwak MS
    Saudi J Gastroenterol; 2018; 24(6):326-335. PubMed ID: 30004042
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Tenofovir Versus Entecavir for Hepatocellular Carcinoma Prevention in an International Consortium of Chronic Hepatitis B.
    Hsu YC; Wong GL; Chen CH; Peng CY; Yeh ML; Cheung KS; Toyoda H; Huang CF; Trinh H; Xie Q; Enomoto M; Liu L; Yasuda S; Tanaka Y; Kozuka R; Tsai PC; Huang YT; Wong C; Huang R; Jang TY; Hoang J; Yang HI; Li J; Lee DH; Takahashi H; Zhang JQ; Ogawa E; Zhao C; Liu C; Furusyo N; Eguchi Y; Wong C; Wu C; Kumada T; Yuen MF; Yu ML; Nguyen MH
    Am J Gastroenterol; 2020 Feb; 115(2):271-280. PubMed ID: 31634265
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Long-Term Efficacy of Tenofovir Disoproxil Fumarate Therapy in Nucleos(t)ide-Experienced Chronic Hepatitis B Patients.
    Huang M; Jie Y; Lin G; Shi H; Li X; Li X; Wu Y; Chong Y
    Clin Drug Investig; 2016 Jun; 36(6):471-8. PubMed ID: 26992717
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prediction of liver-related events using fibroscan in chronic hepatitis B patients showing advanced liver fibrosis.
    Kim SU; Lee JH; Kim DY; Ahn SH; Jung KS; Choi EH; Park YN; Han KH; Chon CY; Park JY
    PLoS One; 2012; 7(5):e36676. PubMed ID: 22574212
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Longitudinal change of liver stiffness by transient elestography in chronic hepatitis B patients treated with nucleos(t)ide analogue.
    Jang W; Yu SI; Sinn DH; Park SH; Park H; Park JY; Jeon TJ; Oh TH; Shin WC; Choi WC
    Clin Res Hepatol Gastroenterol; 2014 Apr; 38(2):195-200. PubMed ID: 24231289
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Using the chronic kidney disease guidelines to evaluate the renal safety of tenofovir disoproxil fumarate in hepatitis B patients.
    Tsai HJ; Chuang YW; Lee SW; Wu CY; Yeh HZ; Lee TY
    Aliment Pharmacol Ther; 2018 Jun; 47(12):1673-1681. PubMed ID: 29696665
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Long-term clinical outcomes in cirrhotic chronic hepatitis B patients treated with tenofovir disoproxil fumarate for up to 5 years.
    Buti M; Fung S; Gane E; Afdhal NH; Flisiak R; Gurel S; Flaherty JF; Martins EB; Yee LJ; Dinh P; Bornstein JD; Mani Subramanian G; Janssen HL; George J; Marcellin P
    Hepatol Int; 2015 Apr; 9(2):243-50. PubMed ID: 25788199
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Five-year comparative risk of hepatocellular carcinoma development under entecavir or tenofovir treatment-naïve patients with chronic hepatitis B-related compensated cirrhosis in Taiwan.
    Hu TH; Yueh-Hsia Chiu S; Tseng PL; Chen CH; Lu SN; Wang JH; Hung CH; Kee KM; Lin MT; Chang KC; Lin MC; Chien RN
    Aliment Pharmacol Ther; 2020 Dec; 52(11-12):1695-1706. PubMed ID: 33111400
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evaluating the efficacy of switching from lamivudine plus adefovir to tenofovir disoproxil fumarate monotherapy in lamivudine-resistant stable hepatitis B patients.
    Lee HJ; Kim SJ; Kweon YO; Park SY; Heo J; Woo HY; Hwang JS; Chung WJ; Lee CH; Kim BS; Suh JI; Tak WY; Jang BK
    PLoS One; 2018; 13(1):e0190581. PubMed ID: 29329305
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Early steep decline of liver stiffness predicts histological reversal of fibrosis in chronic hepatitis B patients treated with entecavir.
    Kong Y; Sun Y; Zhou J; Wu X; Chen Y; Piao H; Lu L; Ding H; Nan Y; Jiang W; Xu Y; Xie W; Li H; Feng B; Shi G; Chen G; Li H; Zheng H; Cheng J; Wang T; Liu H; Lv F; Shao C; Mao Y; Sun J; Chen T; Han T; Han Y; Wang L; Ou X; Zhang H; Jia J; You H
    J Viral Hepat; 2019 May; 26(5):576-585. PubMed ID: 30624000
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prognostic significance of dynamic changes in liver stiffness measurement in patients with chronic hepatitis B and compensated advanced chronic liver disease.
    Yu H; Huang Y; Li M; Jiang H; Yang B; Xi X; Smayi A; Wu B; Yang Y
    J Gastroenterol Hepatol; 2024 Oct; 39(10):2169-2181. PubMed ID: 38946401
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Optimal liver stiffness measurement values for the diagnosis of significant fibrosis and cirrhosis in chronic liver disease in Singapore.
    Chang PE; Hartono JL; Ngai YL; Dan YY; Lim KB; Chow WC
    Singapore Med J; 2019 Oct; 60(10):532-537. PubMed ID: 30556091
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Shear wave elastography for liver fibrosis in chronic hepatitis B: Adapting the cut-offs to alanine aminotransferase levels improves accuracy.
    Zeng J; Zheng J; Jin JY; Mao YJ; Guo HY; Lu MD; Zheng HR; Zheng RQ
    Eur Radiol; 2019 Feb; 29(2):857-865. PubMed ID: 30039224
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.